Single-nucleotide polymorphisms studied for associations with urinary toxicity from (125)I prostate brachytherapy...

Area of Science:

• Oncology
• Urology
• Radiotherapy

Background:

• Prostate brachytherapy using iodine-125 (125I) is a common treatment for localized prostate cancer.
• Late urinary toxicity is a significant concern for patients undergoing this procedure.
• Identifying predictive factors for toxicity is crucial for personalized treatment strategies.

Purpose of the Study:

• To investigate clinical, dosimetric, and genetic factors associated with late urinary toxicity following 125I prostate brachytherapy.
• To explore the role of single-nucleotide polymorphisms (SNPs) in predicting treatment outcomes.

Main Methods:

• Retrospective analysis of 296 men treated with 125I prostate brachytherapy monotherapy.
• Saliva DNA extraction for genotyping of 14 candidate SNPs in 13 genes.
• Correlation analysis of clinical, dosimetric, and genetic data with late urinary toxicity (Grade ≥2).

Main Results:

• A total of 217 men with ≥2 years follow-up were analyzed.
• Late urinary complications occurred in 39 patients.
• Older age was the only significant predictor of late urinary toxicity (p=0.02).
• No tested SNPs were significantly associated with urinary toxicity in univariate analysis.

Conclusions:

• Age is a significant clinical factor associated with late urinary toxicity after 125I prostate brachytherapy.
• The candidate gene approach and limited sample size restrict definitive conclusions.
• Future radiogenomic studies should consider genome-wide association studies (GWAS) for broader insights.